Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Saved in:
| Title: | Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. |
|---|---|
| Authors: | Aldred, Jason1 (AUTHOR) JAldred@selkirkneurology.com, Freire-Alvarez, Eric2 (AUTHOR), Amelin, Alexander V.3 (AUTHOR), Antonini, Angelo4 (AUTHOR), Bergmans, Bruno5,6 (AUTHOR), Bergquist, Filip7 (AUTHOR), Bouchard, Manon8 (AUTHOR), Budur, Kumar9 (AUTHOR), Carroll, Camille10 (AUTHOR), Chaudhuri, K. Ray11,12 (AUTHOR), Criswell, Susan R.13 (AUTHOR), Danielsen, Erik H.14 (AUTHOR), Gandor, Florin15,16 (AUTHOR), Jia, Jia9 (AUTHOR), Kimber, Thomas E.17,18 (AUTHOR), Mochizuki, Hideki19 (AUTHOR), Robieson, Weining Z.9 (AUTHOR), Spiegel, Amy M.9 (AUTHOR), Standaert, David G.20 (AUTHOR), Talapala, Saritha9 (AUTHOR) |
| Source: | Neurology & Therapy. Dec2023, Vol. 12 Issue 6, p1937-1958. 22p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
